相关实验视频

Updated: Sep 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

低剂量阿帕胺在非转移性割抵抗性前列腺癌中:一个病例系列

Minh Dung Nguyen¹, Johan Rose Dite Modestine², Yannick Djoua²

¹King's College Hospital, London, U.K. nguyenmdmd@gmail.com.

Anticancer research

|June 27, 2025

概括

低剂量阿帕胺在治疗非转移性割抵抗性前列腺癌 (nmCRPC) 中表现出有效性. 这表明优化剂量策略的潜力,以改善患者的治疗结果.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

阿帕胺是一种已批准用于前列腺癌的雄激素受体 (AR) 抑制剂.
阿帕胺的最小有效剂量尚未确立.

研究的目的:

评估低剂量阿帕胺在患有非转移性割抵抗性前列腺癌 (nmCRPC) 患者的疗效.

主要方法:

对接受≤60 mg/天阿帕胺的nmCRPC患者的回顾性图表审查.
纳入标准:确诊的前列腺癌,PSA升高,没有远程转移,丸激素低.
在第12周,PSA应答被定义为>50%降低;结果与剂量升级研究数据相比.

主要成果:

分析了6名患有nmCRPC的老年患者 (平均年龄为81.1岁).
所有患者在12周实现了PSA降低 (p=0.031),达到50%的PSA降低的中位时间为21.6天.
在6名患者中,有5名患者存活了2.44年的中位随访期,其中一些患者实现了无法检测的PSA或稳定的疾病.

结论:

低剂量阿帕胺在nmCRPC患者的这个小病例系列中显示出有效性.
拟议的阿帕胺剂量流程图可能有助于个性化治疗并避免更高的剂量.
需要进一步的剂量反应研究来确认最佳的阿帕胺剂量.

关键词:

在ARN-509中使用.亚帕胺胺是什么意思?药物剂量-反应关系.最大的耐受剂量.前列腺新生体前列腺瘤.减少剂量的减少剂量

更多相关视频

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...